Présentation de l'entreprise
Purple Biotech Ltd. operates as a clinical-stage biotechnology firm dedicated to the development of novel therapies designed to overcome tumor immune evasion and drug resistance in cancer patients within the United States. The company's oncology pipeline specifically features CM24, a humanized monoclonal antibody engineered to block the interactions of carcinoembryonic antigen, representing a focused effort to address specific biological barriers in oncology treatment. This entity functions within the broader Healthcare sector, specifically the Biotechnology industry, where capital allocation is heavily weighted towards research and development rather than immediate commercialization. With a market capitalization of $6.47M and an employee count of 10, the company represents a micro-cap entity with a highly concentrated workforce. The extremely low market cap relative to typical pharmaceutical peers indicates that the company is in a pre-revenue or early-stage development phase, where the primary value proposition lies in the potential future approval of its pipeline assets rather than current operational cash flows or established sales volumes.
Santé financière
The company reported a net income of $-26,386,000 over the trailing twelve months, while revenue data is unavailable, highlighting a significant gap between reported losses and top-line generation typical of clinical-stage development models. The EBITDA stands at $-6,973,000, suggesting that even before interest, taxes, depreciation, and amortization, the core business operations are generating substantial negative cash conversion due to the high costs associated with clinical trials and research activities. Free cash flow is reported at $-54,000, which indicates that the company is currently consuming cash reserves to fund its operations and development pipeline without generating operational liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a business model where no commercial revenue has been recognized to date, rendering traditional margin analysis inapplicable to this stage of development. On the balance sheet, the company holds $9.57M in cash against $244,000 in debt, resulting in a debt-to-equity ratio of 2.53, which suggests a capital structure heavily reliant on equity financing and existing cash reserves rather than debt servicing. Despite the high leverage ratio relative to a cash-rich position, the current ratio of 1.27 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer for its ongoing operational expenditures. Return on Equity is -124.5% and Return on Assets is -16.0%, metrics that reveal management is currently deploying capital to generate value through future asset appreciation and clinical success rather than immediate profitability, a common characteristic of early-stage biotech firms.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable (N/A) due to negative earnings, while the forward P/E is listed as -6.61, implying that the market anticipates continued negative earnings or a normalization of losses in the near term rather than immediate profitability. The price-to-book ratio is exceptionally high at 846.00, indicating that the market values the company at a massive premium over its net book value, a standard valuation behavior for clinical-stage assets where the intangible value of the pipeline vastly exceeds the tangible assets on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio (N/A) and the EV/EBITDA of -1126.32 further underscore that traditional multiple-based valuation is ineffective, as the company has no sales and negative earnings, forcing investors to rely on pipeline potential rather than financial multiples. The stock has traded between a 52-week low of $3.60 and a 52-week high of $29.40, showing a wide trading range that reflects the high volatility typical of small-cap biotechnology stocks with binary event-driven risk profiles. The beta of -0.70 is anomalous for equities and suggests an inverse correlation to the broader market, meaning the stock tends to move in the opposite direction of the market index, adding a layer of idiosyncratic risk that is not captured by standard beta calculations used in portfolio theory.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated commercial revenue, meaning that growth rates cannot be calculated based on historical financial performance data. In the absence of dividend distributions, the dividend yield is N/A and the payout ratio is 0.0%, which is consistent with the company's strategy of reinvesting all available resources, including its $9.57M cash balance, into advancing its clinical pipeline and conducting further research rather than returning capital to shareholders. The company does not pay dividends, and the zero payout ratio confirms that all financial focus is directed toward sustaining operations and funding the development of CM24 and other pipeline assets until they reach commercial viability. The overall growth and income profile is characterized by a complete absence of current income generation, relying entirely on the successful execution of future clinical milestones to unlock shareholder value.